Posted by Michael Wonder on 26 May 2020
Ofev (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases
25 May 2020 - Ofev slowed lung function decline in PF-ILD patients by 57% compared to placebo.
Boehringer Ingelheim announced today that Ofev (nintedanib) is authorised for sale by Health Canada for the treatment of other chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype (also known as progressive fibrosing ILD).
Interstitial lung diseases (ILDs) encompass more than 200 disorders that can lead to irreversible scarring of lung tissue, negatively impacting lung function.
